Evelyn Ning Man Cheung1, Susan R George2, Danielle M Andrade3, Eva W C Chow4, Candice K Silversides5, Anne S Bassett6. 1. Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. 2. 1] Neuroscience Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Department of Medicine, University of Toronto, Toronto, Ontario, Canada [3] Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada [4] Dalglish Family Hearts and Minds Clinic, University Health Network, Toronto, Ontario, Canada. 3. 1] Dalglish Family Hearts and Minds Clinic, University Health Network, Toronto, Ontario, Canada [2] Division of Neurology, Krembil Neuroscience Centre, Epilepsy Genetics Program, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. 4. 1] Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. 5. 1] Department of Medicine, University of Toronto, Toronto, Ontario, Canada [2] Dalglish Family Hearts and Minds Clinic, University Health Network, Toronto, Ontario, Canada [3] Division of Cardiology, Department of Medicine, University Health Network, Toronto, Ontario, Canada [4] Toronto Congenital Cardiac Centre for Adults, Toronto General Hospital, Toronto, Ontario, Canada [5] Obstetric Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada. 6. 1] Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada [2] Dalglish Family Hearts and Minds Clinic, University Health Network, Toronto, Ontario, Canada [3] Division of Neurology, Krembil Neuroscience Centre, Epilepsy Genetics Program, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada [4] Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada [5] Division of Cardiology, Department of Medicine, University Health Network, Toronto, Ontario, Canada [6] Toronto Congenital Cardiac Centre for Adults, Toronto General Hospital, Toronto, Ontario, Canada [7] Obstetric Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada [8] Department of Psychiatry, University Health Network, Toronto, Ontario, Canada.
Abstract
PURPOSE: Hypocalcemia is a common endocrinological condition in 22q11.2 deletion syndrome. Neonatal hypocalcemia may affect neurodevelopment. We hypothesized that neonatal hypocalcemia would be associated with rare, more severe forms of intellectual disability in 22q11.2 deletion syndrome. METHODS: We used a logistic regression model to investigate potential predictors of intellectual disability severity, including neonatal hypocalcemia, neonatal seizures, and complex congenital heart disease, e.g., interrupted aortic arch, in 149 adults with 22q11.2 deletion syndrome. Ten subjects had moderate-to-severe intellectual disability. RESULTS: The model was highly significant (P < 0.0001), showing neonatal seizures (P = 0.0018) and neonatal hypocalcemia (P = 0.047) to be significant predictors of a more severe level of intellectual disability. Neonatal seizures were significantly associated with neonatal hypocalcemia in the entire sample (P < 0.0001), regardless of intellectual level. There was no evidence for the association of moderate-to-severe intellectual disability with other factors such as major structural brain malformations in this sample. CONCLUSION: The results suggest that neonatal seizures may increase the risk for more severe intellectual deficits in 22q11.2 deletion syndrome, likely mediated by neonatal hypocalcemia. Neonatal hypocalcemia often remains unrecognized until the postseizure period, when damage to neurons may already have occurred. These findings support the importance of early recognition and treatment of neonatal hypocalcemia and potentially neonatal screening for 22q11.2 deletions.
PURPOSE: Hypocalcemia is a common endocrinological condition in 22q11.2 deletion syndrome. Neonatal hypocalcemia may affect neurodevelopment. We hypothesized that neonatal hypocalcemia would be associated with rare, more severe forms of intellectual disability in 22q11.2 deletion syndrome. METHODS: We used a logistic regression model to investigate potential predictors of intellectual disability severity, including neonatal hypocalcemia, neonatal seizures, and complex congenital heart disease, e.g., interrupted aortic arch, in 149 adults with 22q11.2 deletion syndrome. Ten subjects had moderate-to-severe intellectual disability. RESULTS: The model was highly significant (P < 0.0001), showing neonatal seizures (P = 0.0018) and neonatal hypocalcemia (P = 0.047) to be significant predictors of a more severe level of intellectual disability. Neonatal seizures were significantly associated with neonatal hypocalcemia in the entire sample (P < 0.0001), regardless of intellectual level. There was no evidence for the association of moderate-to-severe intellectual disability with other factors such as major structural brain malformations in this sample. CONCLUSION: The results suggest that neonatal seizures may increase the risk for more severe intellectual deficits in 22q11.2 deletion syndrome, likely mediated by neonatal hypocalcemia. Neonatal hypocalcemia often remains unrecognized until the postseizure period, when damage to neurons may already have occurred. These findings support the importance of early recognition and treatment of neonatal hypocalcemia and potentially neonatal screening for 22q11.2 deletions.
Authors: A S Bassett; E W C Chow; J Husted; K A Hodgkinson; E Oechslin; L Harris; C Silversides Journal: J Med Genet Date: 2009-02-25 Impact factor: 6.318
Authors: Anne S Bassett; Donna M McDonald-McGinn; Koen Devriendt; Maria Cristina Digilio; Paula Goldenberg; Alex Habel; Bruno Marino; Solveig Oskarsdottir; Nicole Philip; Kathleen Sullivan; Ann Swillen; Jacob Vorstman Journal: J Pediatr Date: 2011-05-12 Impact factor: 4.406
Authors: Chloe A Joynt; Charlene M T Robertson; Po-Yin Cheung; Alberto Nettel-Aguirre; Ari R Joffe; Reg S Sauve; Wayne S G Biggs; Norma J Leonard; David B Ross; Ivan M Rebeyka Journal: J Thorac Cardiovasc Surg Date: 2009-06-23 Impact factor: 5.209
Authors: A Swillen; L Vandeputte; J Cracco; B Maes; P Ghesquière; K Devriendt; J P Fryns Journal: Child Neuropsychol Date: 1999-12 Impact factor: 2.500
Authors: Eric H Kossoff; Mary T Silvia; Alexander Maret; Mauri Carakushansky; Eileen P G Vining Journal: J Child Neurol Date: 2002-03 Impact factor: 1.987
Authors: Nancy J Butcher; Erik Boot; Anthony E Lang; Danielle Andrade; Jacob Vorstman; Donna McDonald-McGinn; Anne S Bassett Journal: Am J Med Genet A Date: 2018-05-19 Impact factor: 2.802
Authors: Lisa D Palmer; Nancy J Butcher; Erik Boot; Kathleen A Hodgkinson; Tracy Heung; Eva W C Chow; Alina Guna; T Blaine Crowley; Elaine Zackai; Donna M McDonald-McGinn; Anne S Bassett Journal: Am J Med Genet A Date: 2018-04 Impact factor: 2.802
Authors: Chrystal Chan; Gregory Costain; Lucas Ogura; Candice K Silversides; Eva W C Chow; Anne S Bassett Journal: J Genet Couns Date: 2015-01-13 Impact factor: 2.537
Authors: Donna M McDonald-McGinn; Kathleen E Sullivan; Bruno Marino; Nicole Philip; Ann Swillen; Jacob A S Vorstman; Elaine H Zackai; Beverly S Emanuel; Joris R Vermeesch; Bernice E Morrow; Peter J Scambler; Anne S Bassett Journal: Nat Rev Dis Primers Date: 2015-11-19 Impact factor: 52.329
Authors: James J Yi; Sunny X Tang; Donna M McDonald-McGinn; Monica E Calkins; Daneen A Whinna; Margaret C Souders; Elaine H Zackai; Elizabeth Goldmuntz; James W Gaynor; Ruben C Gur; Beverly S Emanuel; Raquel E Gur Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2013-11-22 Impact factor: 3.568
Authors: Katheryn Grand; Lorraine E Levitt Katz; T Blaine Crowley; Edward Moss; Megan Lessig; Vaneeta Bamba; Katherine Lord; Elaine H Zackai; Beverly S Emanuel; Kathleen Valverde; Donna M McDonald-McGinn Journal: Am J Med Genet A Date: 2018-10 Impact factor: 2.802